136 related articles for article (PubMed ID: 2205353)
1. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables.
Epelbaum R; Faraggi D; Ben-Arie Y; Ben-Shahar M; Haim N; Ron Y; Robinson E; Cohen Y
Cancer; 1990 Sep; 66(6):1124-9. PubMed ID: 2205353
[TBL] [Abstract][Full Text] [Related]
2. Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma.
Utsu Y; Takaishi K; Inagaki S; Arai H; Yuasa H; Masuda S; Matsuura Y; Aotsuka N; Wakita H
Ann Hematol; 2016 Jan; 95(1):41-47. PubMed ID: 26435364
[TBL] [Abstract][Full Text] [Related]
3. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma.
Epelbaum R; Haim N; Ben-Shahar M; Ron Y; Cohen Y
Isr J Med Sci; 1988; 24(9-10):533-8. PubMed ID: 3060443
[TBL] [Abstract][Full Text] [Related]
4. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
5. ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma.
Martinelli G; Ferrucci PF; Mingrone W; Cocorocchio E; Conconi A; Peccatori FA; De Luzio K; Santoro P; Mazzetta C; Zucca E; Cavalli F
Leuk Lymphoma; 2003 May; 44(5):801-6. PubMed ID: 12802917
[TBL] [Abstract][Full Text] [Related]
6. The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.
Długosz-Danecka M; Szmit S; Ogórka T; Skotnicki AB; Jurczak W
Cancer Med; 2019 Mar; 8(3):1103-1109. PubMed ID: 30740919
[TBL] [Abstract][Full Text] [Related]
7. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy.
Donnelly GB; Glassman J; Long C; Torres P; Straus DJ; O'Brien JP; Bertino J; Moskowitz CH; Zelenetz AD; Portlock CS
Leuk Lymphoma; 2000 Sep; 39(1-2):67-75. PubMed ID: 10975385
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of large cell lymphoma].
Cohen Y; Epelbaum R; Ben-Shahar M; Haim N; Ron Y
Harefuah; 1989 Dec; 117(12):417-20. PubMed ID: 2695424
[TBL] [Abstract][Full Text] [Related]
11. Treatment of diffuse histiocytic and diffuse mixed non-Hodgkin lymphomas with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP).
Cohen Y; Epelbaum R; Ben-Shahar M; Ron Y; Haim N
Acta Oncol; 1988; 27(5):531-5. PubMed ID: 3203011
[TBL] [Abstract][Full Text] [Related]
12. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
13. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
14. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
15. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF
Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653
[TBL] [Abstract][Full Text] [Related]
16. Rituximab as consolidation therapy did not improve outcome in patients with diffuse large B-cell lymphoma at complete response after dose-dense chemotherapy (CHOP-14).
Avilès A; Nambo MJ; Huerta-Guzmàn J; Silva L; Neri N
Cancer Biother Radiopharm; 2015 Apr; 30(3):107-10. PubMed ID: 25871407
[TBL] [Abstract][Full Text] [Related]
17. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
[TBL] [Abstract][Full Text] [Related]
18. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
20. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.
Bosly A; Bron D; Van Hoof A; De Bock R; Berneman Z; Ferrant A; Kaufman L; Dauwe M; Verhoef G
Ann Hematol; 2008 Apr; 87(4):277-83. PubMed ID: 17952688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
